L-Noradrenalina Braun (Noradrenaline Tartrate)

L‑Noradrenalina Braun, a sympathomimetic vasopressor, is employed in critical care to manage severe circulatory failure.

• Hypotension: restores systemic vascular resistance, increasing arterial pressure in acute low‑blood‑pressure states.
• Septic shock: counteracts profound vasodilation, supporting organ perfusion during severe infection‑induced hypotension.
• Cardiac arrest: provides vasoconstrictive support to improve coronary and cerebral blood flow during resuscitation efforts.
• Neurogenic shock: elevates blood pressure when spinal cord injury causes loss of sympathetic tone.

• Noradrenaline tartrate acts as a direct agonist at α1‑adrenergic receptors on vascular smooth muscle, inducing potent vasoconstriction and raising systemic vascular resistance. It also stimulates β1‑adrenergic receptors in the heart, modestly increasing cardiac contractility and rate. The combined α‑mediated vasoconstriction and β‑mediated cardiac effects rapidly elevate arterial pressure, making it effective in acute hypotensive states. These actions are dose‑dependent and are rapidly reversible upon discontinuation.

Noradrenaline tartrate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Headache: transient cranial pain due to vasoconstriction.
• Tachycardia: increased heart rate from β1 stimulation.
• Arrhythmia: irregular cardiac rhythm, especially in predisposed patients.
• Peripheral ischemia: reduced blood flow to extremities causing coldness or pain.
• Nausea: gastrointestinal discomfort.

Serious or Rare Side Effects

• Severe hypertension: abrupt, dangerous rise in blood pressure.
• Myocardial ischemia: reduced heart muscle oxygen leading to chest pain.
• Tissue necrosis: local skin or limb damage from extravasation.
• Pulmonary edema: fluid accumulation in lungs causing respiratory distress.
• Cardiac arrest: life‑threatening cessation of heart activity.

When using L‑Noradrenalina Braun, clinicians should observe several safety measures to minimize risk.

• Dose titration: adjust infusion rate based on continuous blood pressure monitoring.
• Cardiac monitoring: observe heart rhythm and signs of ischemia during therapy.
• Fluid status: ensure adequate intravascular volume before initiating infusion.
• Drug interactions: avoid concurrent use with MAO inhibitors or other potent vasopressors without supervision.
• Extravasation risk: monitor infusion site for signs of leakage and stop immediately if observed.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Noradrenaline tartrate can interact with several agents, altering its efficacy or safety profile.

Major Interactions (Avoid)

• MAO inhibitors: may cause excessive hypertensive response.
• β‑blockers: can blunt β1‑mediated cardiac effects, leading to unopposed α‑vasoconstriction.
• Tricyclic antidepressants: increase risk of severe hypertension.

Moderate Interactions (Monitor Closely)

• Vasodilators (e.g., nitroglycerin): may reduce norepinephrine effectiveness, requiring dose adjustments.
• Calcium channel blockers: can potentiate hypotensive episodes if norepinephrine is withdrawn abruptly.
• Diuretics: may affect intravascular volume, influencing response to vasopressor therapy.